Table 4.

Safety evaluation in blood chemistry between 0–12 weeks intervention.

	Treatment Group (n = 36)			Control Group (n = 40)
	0 Week	12 Weeks	Change from Baseline	0 Week	12 Weeks	Change from Baseline	p-Value **
			(12 Week–0 Week)			(12 Week–0 Week)
AST (IU/L)	24.28 ± 6.53	23.19 ± 4.49	−1.44 ± 6.06	24.62 ± 6.83	23.19 ± 4.91	−1.57 ± 5.59	0.880
ALT (IU/L)	20.66 ± 10.46	17.55 ± 6.66	−3.42 ± 8.58	21.82 ± 11.46	19.83 ± 9.49	−2.44 ± 8.32	0.454
Total protein (g/dL)	7.48 ± 0.39	7.46 ± 0.39	−0.01 ± 0.42	7.50 ± 0.39	7.50 ± 0.35	0.01 ± 0.31	0.566
Albumin (g/dL)	4.42 ± 0.22	4.40 ± 0.24	−0.02 ± 0.25	4.46 ± 0.24	4.46 ± 0.24	0.00 ± 0.19	0.678
Glucose (mg/dL)	93.82 ± 7.90	90.77 ± 6.88	−3.00 ± 9.30	94.21 ± 9.63	93.32 ± 11.84	−1.32 ± 12.28	0.548
Total bilirubin (mg/dL)	0.69 ± 0.25	0.69 ± 0.24	−0.01 ± 0.27	0.61 ± 0.23	0.64 ± 0.23	0.03 ± 0.21	0.445
ALP (IU/L)	62.45 ± 16.47	63.53 ± 16.09	1.14 ± 7.16	61.48 ± 16.70	61.87 ± 14.94	0.24 ± 6.90	0.499
Na+ (mmol/L)	138.43 ± 2.18	139.03 ± 1.83	0.72 ± 1.94	138.77 ± 1.72	139.10 ± 1.67	0.27 ± 2.14	0.222
K+ (mmol/L)	4.22 ± 0.37	4.17 ± 0.43	−0.07 ± 0.52	4.28 ± 0.38	4.28 ± 0.49	0.03 ± 0.53	0.433
Cl− (mmol/L)	103.70 ± 1.80	104.23 ± 2.01	0.53 ± 1.98	103.86 ± 1.67	104.32 ± 1.77	0.41 ± 2.04	0.844
Ca2+ (mmol/L)	9.06 ± 0.37	9.15 ± 0.34	0.10 ± 0.45	9.14 ± 0.38	9.23 ± 0.34	0.09 ± 0.36	0.817
CK (mg/dL)	118.68 ± 163.52	100.30 ± 35.13	−25.31 ± 171.08	109.08 ± 56.49	113.68 ± 48.07	6.05 ± 48.72	0.178
Creatinine (mg/dL)	0.65 ± 0.09	0.67 ± 0.09	0.02 ± 0.07	0.66 ± 0.10	0.69 ± 0.10	0.03 ± 0.06	0.435
BUN (mg/dL)	13.09 ± 3.59	13.59 ± 3.78	0.38 ± 3.36	13.40 ± 4.11	13.63 ± 4.95	0.19 ± 4.17	0.853
Uric acid (mg/dL)	4.71 ± 1.06	4.79 ± 1.02	0.06 ± 0.73	4.66 ± 0.91	4.77 ± 0.91	0.11 ± 0.53	0.598
γ-GTP (IU/L)	18.59 ± 9.60	16.30 ± 6.60	−2.25 ± 5.23	21.40 ± 20.71	21.62 ± 21.52	−0.60 ± 8.88	0.255

**: Compared within groups; p-value for paired t-test.